About Dr. Henderson
I have extensive clinical and research expertise in thyroid cancer. My background in chemistry and 3-year research fellowship in endocrinology has allowed time and development of basic research skills that I am able to translate to the clinic. During my time at Duke, I successfully obtained research funding in thyroid cancer and thyroid hormone metabolism through the American Thyroid Association (ATA), the Endocrine Fellows Foundation (EFF), and the American Association for the Study of Liver Diseases (AASLD). My original research was the first to describe Hedgehog signaling in medullary thyroid cancer, intrahepatic hypothyroidism as a direct indicator of liver fibrosis in non-alcoholic fatty liver disease (NAFLD), and LGR5 overexpression in human papillary thyroid cancer (PTC) as a marker of tumor aggressiveness. My work has been featured on the cover of Thyroid and has been presented at multiple national and international conferences. After fellowship, I joined the Duke faculty with clinical focus in thyroid disease and thyroid cancer. I built a strong clinical expertise in thyroid ultrasound and fine needle aspiration biopsy, perioperative lymph node mapping, percutaneous ethanol ablation, and was the first ECNU-certified physician at my institution (endocrine ultrasound certification recognized by the American Institute for Ultrasound Medicine). I organized the Endocrine Tumor Board and worked as a clinical thyroid expert in our multidisciplinary endocrine neoplasia clinic, recruiting heavily for clinical trials in advanced thyroid cancer. I have participated as faculty at the national and international level through the ATA and through ThyCa, the patient advocacy group for thyroid cancer. Upon transitioning to a faculty position at Wake Forest Baptist Medical Center, I again organized a multidisciplinary tumor board for thyroid cancer and endocrine neoplasia. I am Director of the Thyroid and Endocrine Neoplasia Clinic in the Comprehensive Cancer Center. My clinics encompass multidisciplinary services including: endocrine surgery, thyroidology, radiology, and on-site cytology services. Both my research background and my clinical training have given me the expertise in thyroid disease and thyroid cancer needed to positively impact future thyroid care.
Click here to read Dr. Henderson’s CV.
|Education and Training|
|Northeastern Ohio Universities College of Medicine graduated 2007|
|Residency in Internal Medicine, New Hanover Regional Medical Center; 2010|
|Fellowship in Endocrinology, Diabetes, and Metabolism, Duke University Medical Center; 2013|
|Current Academic Appointment|
|Director, Thyroid & Endocrine Neoplasia Clinics, Wake Forest Baptist Comprehensive Cancer Center Assistant Professor of Medicine|
|Internal Medicine, Endocrinology, Diabetes, and Metabolism|
Director, Thyroid & Endocrine Neoplasia Clinics, Assistant Professor of Medicine
1 Medical Center Blvd
Winston Salem, NC 27157
- My early publications focused on different facets of endocrine diseases including: diabetes mellitus, osteoporosis, adrenal incidentalomas, parathyroid disease, and thyroid cancer. During this time of my career, my work focused on improving diabetes care in the residency clinic, bringing awareness to secondary causes of osteoporosis, and presenting new and usual cases in endocrinology. I wrote multiple invited book chapters and journal articles on biased agonism at the parathyroid receptor and contributed my first article to Thyroid describing an usual case of thyroid microcarcinoma and ectopic thyroid tissue in the adrenal gland.
- Bohinc B., Snyder J.E. (2008) The Effects of Race, Ethnicity, and Underlying Medical Disease on Osteoporosis Are Still Unguided Territory for Internists. Annals of Internal Medicine. 149 (7), 514-515. PMID:18838734
- Bohinc BN, Gesty-Palmer D (2011) Skeletal Effects of B-arrestin-Biased Agonism at the Parathyroid Hormone Receptor: Biased Agonism at the Parathyroid Hormone Receptor Uncouples Bone Formation from Bone Resorption. Hot Topics Issue of Endocrine, Metabolic and Immune Disorders-Drug Targets. 11(2), 112-9. PMID: 21476967.
- Bohinc B, Parker J, Hope W, Kotwall C, Turner J, Cheng W, Lloyd R. (2011) Micropapillary Thyroid Carcinoma and Concomitant Ectopic Thyroid Tissue in the Adrenal Gland: Metastasis or Metaplasia? Thyroid 2011. Volume 21, Number 8. PMID: 21834675.
- As my career progressed, I began to focus on thyroid hormone metabolism and its interaction with various disease states, particularly nonalcoholic fatty liver disease (NAFLD). I spent three years as a basic and translational research in Anna Mae Diehl’s laboratory. Our work was the first to describe intrahepatic hypothyroidism as an indicator of fibrosis severity in NAFLD. Using animal models and the Duke Human NAFLD Biorepository, we demonstrated that serum freeT3/reverse T3 was inversely associated with histologic fibrosis stage. Additionally we demonstrated that the inactivating thyroid hormone (TH) enzyme (deiodinase 3; D3) is upregulated in liver nonparenchymal cells (specifically, in myofibroblasts) while the activating enzyme (deiodinase 1; D1) is downregulated in hepatocytes. The degree of this D1/D3 switch is directly proportional to the liver injury severity and is more pronounced as fibrosis progresses. Our findings were supported by liver microarray data for TH-responsive genes and demonstrated in wild type animals, transgenic animals (alphaSMACre-Smo flx/flx mice), and in human NAFLD patients (n=130). Our work was the first to suggest that Hedgehog-regulated hepatic stromal cell responses that occur during adult liver repair shift the balance of local deiodinase expression to favor accumulation of biologically inert TH at the expense of biologically-active TH. Our data suggests that this ‘switch’ may alter hepatic differentiation, as well as systemic TH homeostasis, thereby contributing to negative outcomes of liver injury. As such, D3 may be a new therapeutic target in liver fibrosis, and its product, rT3, a novel biomarker in that process.
- Bohinc BN, Diehl AM (2012) Mechanisms of Disease Progression in NASH: New Paradigms. Clinics in Liver Disease. 16(3): 549-65. PMID: 22824480
- Bohinc B, Michelotti G, Xie G, Pang H, Suzuki A, Guy CD, Piercy D, Kruger L, Swiderska-Syn M, Macado M, Pereira T, Marie Zavacki A, Abdelmalek M, Mae Diehl A. Repair-related Activation of Hedgehog Signaling in Stromal Cells Promotes Intrahepatic Hypothyroidism. Endocrinology. 2014; 155(11): 4591-601. PMID: 25121996
- Machado MV, Michelotti GA, Xie G, de Almeida TP, Boursier J, Bohinc B, Guy CD, Diehl AM. Mouse Models of Diet-Induced Nonalcoholic Steatohepatitis Reproduce the Heterogeneity of Human Disease. PLoS One. 2015 Jun 29; 10(6): e0132315. Doi: 10.1371/journal.pone.0132315
- Machado M, Michelotti G, Pereira TD, Boursier J, Kruger L, Swiderska-Syn M, Karaca G, Xie G, Guy CD, Bohinc B, Lindblom KR, Johnson E, Kornbluth S, Diehl AM. Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis. Gut. 2015; 64(7): 1148-57.
- Because my main research and clinical interest has always been in thyroid cancer and endocrine neoplasia, I have also contributed to science in this field. I was the first to describe Hedgehog signaling in medullary thyroid cancer. I have also contributed to invited book chapters and review articles. Most notably, I was awarded a national research award through the American Thyroid Association (ATA) to support my novel work describing LGR5 overexpression in thyroid cancer and its association with tumor aggressiveness. My work was featured on the cover of Thyroid.
- Bohinc B, Michelotti G, Diehl AM. (2013) Hedgehog Signaling in Medullary Thyroid Cancer: A Novel Signaling Pathway. Thyroid . 23(9): 1119-26. PMID:23410206.
- Bohinc BN, Perkins JM. Appropriate dosing of adjuvant radioactive iodine for differentiated thyroid cancer. Curr Opin Oncol. 2014; 26(1): 31-5. PMID: 24225414
- Henderson JH and Bohinc Henderson B (2015). Imaging the Thyroid in Health and Disease. In Press.
- Henderson JH and Bohinc Henderson B (2015). Thyroid Nodules: Work-up and Modern Concepts. In Press.
- Michelotti G, Diehl AM, Sosa JA, Bohinc Henderson B. (2015) LGR5 Overexpression in Papillary Thyroid Carcinoma Promotes Tumor Aggressiveness. Oncotarget. 2015 Oct 27; 6(33): 345-60. PMID: 26416247.
- Tucker JM, Ahmed S, Burns C, Henderson BB (2017). Case Report: The Utility of PTH Needle Washout in Distinguishing Recurrent Thyroid Bed Lesions in Thyroid Cancer Patients at Risk for Hyperparathyroidism. Clinical Thyroidology; 29(5): 200-204.
Complete List of Published Work: